TABLE 6.

Highly reactive regions to be included in vaccine design^a

OLP	Protein	Sequence	Lengthb
11-12	Gag-p17	TGSEELRSLYNTVATLYCVHQRIEVKDTKEALEK	34
22-25	Gag-p24	WVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKE	49
28-30	Gag-p24	LKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTS	41
35-37	Gag-p24	WMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKE	43
40-42	Gag-p24	GPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDC	43
59	Gag-p15	TRRQANFLGKIWPSHKGRPGNFLQSRP	27
281	Vpr	ELKNEAVRHFPRIWLHSLGQHIYETYG	27
293-295	gp120	AAEQLWVTVYYGVPVWKEATTTLFCASDACAYDTEVHNVWA	41
75-79	Nef	WLEAQEEEEVGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIYSQKRQDILDLWV	58
81-85	Nef	QKRQDILDLWVYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEAN	25

^aPeptides were included when recognized by at least 20% of the overall population, and adjacent peptides were added when targeted by >10% of the overall cohort.

^bNumber of amino acids.